AITL is rare accounting for about 2% of all non-Hodgkin lymphomas (11) . There have been relatively little data concerning the impact of clinical, biological and morphological features of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) and/or AITL on survival and outcome (12) (13) (14) (15) (16) (17) (18) . In this report, we attempted to identify the prognostic significance of different pathological, biological and clinical parameters after a long follow-up of consecutive AITL patients treated with 6 chemotherapy according to LNH87 and LNH93 protocols conducted by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). In particular, since rare cases of B-cell lymphomas have been reported to arise after AILD (4-5) and since it was suggested that the increase in T-cells could evolve into a PTCL/U (3), we intended to study the prognostic relevance of the increase (>10%) in large atypical cells, irrespective of their B or T-cell phenotype.
Patients and methods

Patient selection:
Eligibility criteria for this study included patients with confirmed diagnosis of AITL To uncover the prognostic significance of the increase in large cells, cases were assigned to 2 major categories: "rich in large cells" (> 10% large B and/or T cells) and "classic", the latter including cases rich in clear cells, rich in epithelioid cells, and with hyperplastic germinal centers ( fig 1A-1E ).
Immunohistochemical analysis:
Immunohistochemistry was performed on deparaffinized tissue sections using an indirect immunoperoxidase method. After appropriate antigen retrieval, slides were stained for CD20, CD3ε and as far as possible CNA42 and/or CD21 antigens (DakoCytomation, Glostrup, Denmark). 36% of cases were tested for the presence of EBV using antibodies to latent membrane protein-1 (DakoCytomation) and/or in situ hybridization with probes specific for the EBV encoded small RNA (EBERs)
sequences. Finally, 62 cases for which additional slides were available, were evaluated for CD10 (56C6; Novocastra, Newcastle, UK) and CXCL13 (R&D systems, 
Statistical analysis:
Patients' characteristics and remission rates were compared using chi-squared test.
Event-free survival (EFS) was defined as the time interval between randomization to primary treatment failure, relapse and death from any cause or last follow-up. Overall survival (OS) was defined as the time interval between randomization to last followup or death from any cause. Estimates of survival were calculated according to the Kaplan-Meier method (33) and were compared using the log-rank test (34) . Cox
proportional-hazards regression analysis with OS and EFS as the dependent variables was used to detect potential independent prognostic factors. Differences were considered statistically significant when the two-sided p value was less than 0.05. All statistical analyses were performed using the Statistical Application System software (SAS, version 9, SAS institute, Cary, NC).
Results
Clinical and biological characteristics of AITL patients at presentation:
Between April 1987 and October 1999, 157 patients were included in the study. Table 1 could not be determined -were observed in 12% and CD10 was negative (score 0) in 17% of our cases. 45 out of 62 sections were adequate for CXCL13 interpretation.
CXCL13 staining was found, as a dot reinforcement of the Golgi area, in aggregates or sheets of atypical cells (score 2+3) in 73% of cases, and in scattered lymphoid cells (score 1) in the remaining 27%. Overall, at least one marker was scored positive in 86% of the interpretable cases and both markers were negative in 14% of them.
Clinical outcome and prognostic parameters:
All but 10 patients received an anthracycline-based chemotherapy. CR/CRu was achieved in 46% of patients after induction therapy and 41% were in CR/CRu at the end of therapy. Overall, the two populations "classic" and "rich in large cells" were not statistically different in terms of clinical features, laboratory findings and treatment response (p=0.676) except for a higher frequency of elevated serum LDH (p=0.027) and β2 microglobulin levels (p=0.046) within the group "rich in large cells".
Furthermore, no difference could be observed between the different chemotherapeutic regimens, whether the treatment was considered intensive or not. (fig 4) . The different histological subtypes as well as CD10 and CXCL13 scoring did not have any influence on survival.
Discussion
In the present series of 157 AITL patients -the largest reported so far in which patients were included in randomized clinical trials -we further extend the peculiar clinical and biological findings of AITL and confirm its poor prognosis despite a firstline anthracycline-based chemotherapy with a curative intent in most patients. We also emphasize its morphologic heterogeneity as well as the common expression of CD10 and CXCL13 determined on routinely-fixed samples.
In keeping with previous reports (12-18, 36-38), we observed that AITL is a disease of the elderly presenting with systemic manifestations and features known to be poor prognostic factors for B-cell lymphomas: 54% of our patients were more than 60 years old, 50% had an altered PS, 81% presented with stage III-IV disease, 46% had more than one extranodal site involvement and 66% had an elevated LDH level. The clinical symptoms and biological signs are not specific of AITL but their association appears to be very suggestive of the disease. Notably, skin rash (44%), arthritis/arthralgia (16%), pleural effusion/ascites/edema (26%), hypergammaglobulinemia (50%) and positive Coombs test (33%) appear to represent distinctive manifestations of AITL.
A small number of studies sought to identify prognostic factors in AITL/AILD (12-18), yielding controversial results. Their results might be hampered by the relatively limited number of patients and/or the heterogeneous therapies including prednisolone alone in a proportion of these patients. In the recent literature where the entity was considered as lymphoma, one study (15) found that survival was influenced by age, stage and number of symptoms including B symptoms, rash/pruritus, and LDH and hemoglobin levels, whereas other studies (16) (17) (18) found no reliable clinico-biological prognostic indicator for the disease. In the current study, where overall patients received more intensive chemotherapy compared to these previous reports, multivariate analysis showed that male gender (p=0.002), age ≤ 60y (p=0.008), mediastinal involvement (p=0.017) and anemia (p=0.021) were poor prognostic factors for OS. IPI, extensively used for B-cell lymphomas patients, has also been found to be of prognostic value in some PTCL series comprising AITL and other T-cell lymphomas entities (19, (39) (40) (41) . In keeping with a previous study focusing on AITL (18), we found that IPI is not a significant predictor of survival (p=0.799). The prognostic model "PIT" proposed by Gallamini et al for PTCL/U was neither predictive of survival in the present series (p=0.106) (35) . Moreover, in a previous study published by GELA (19) , hypergammaglobulinemia > 20 g/l and eosinophilia ≥ 0.8x10 9 /l were more often encountered in AITL than in other subtypes of T-cell lymphomas. Overall, these data reinforce the idea that AITL is a distinct entity. Since IPI and hypergammaglobulinemia/ eosinophilia are supposed to reflect tumor load and immune dysregulation respectively, this may suggest that AITL related manifestations would more likely reflect immune dysregulation than tumor burden (7) (8) (9) . The impact of the clinicopathological prognostic index (including age, LDH>normal, non ambulatory PS, Ki67 ≥ 80%) described by Went et al (42) for PTCL/U patients could not be assessed in our AITL series.
In the present series, we emphasize the morphologic heterogeneity of AITL, which could be a source of misdiagnosis to poorly experienced pathologists, especially concerning cases with hyperplastic germinal centers and rich in epithelioid cells, the latter can be mistaken as Lennert's lymphoma or Hodgkin lymphoma. This is reflected by the large error rate (50%) in the referred cases described by Attygalle et al (7) and by our very low recruitment of cases with hyperplastic germinal centers, a pattern which has recently received attention since it was described in 1998 (43) . It has been recently shown that CXCL13, a chemokine critically involved in B-cell migration into germinal centers, was highly up-regulated in the follicular T helper cell subset (45) (46) (47) . Subsequently, we and others have shown that CXCL13 was expressed by neoplastic cells of most AITLs (9-10). CD10 and CXCL13 were proposed as sensitive immunohistochemical markers in AITL (7, 9, 10) . This finding 15 was confirmed in the present study where at least one marker stained clusters of atypical lymphocytes in the majority (86%) of cases. However, in the few cases (14%) where it was difficult to assign the neoplastic nature for the rare scattered stained cells on pure morphological grounds, both markers were considered negative. In such circumstances, the diagnosis of AITL should rely on a combination of classical morphological criteria together with clinical and biological features.
Despite of various intensive regimens with an anthracycline-based chemotherapy, AITL, compared to other non-Hodgkin lymphomas, pursues an aggressive clinical course, so the optimal therapeutic regimen remains to be determined. AITL does not present any pertinent prognostic factor besides, naturally, the achievement of a complete response to therapy. However, after a long follow-up, we observed a trend for a plateau level reaching a survival probability of around 30% at 6 years. A longer follow-up is further needed to determine whether these patients are eventually cured of their disease. 
